Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2022 | Sanofi profit gain beats market view on bestseller drug Dupixent | RE |
2022 | Sanofi to float drug ingredients manufacturing business on May 6 | RE |
Sales 2008 | 22.12K 30.23K | Sales 2009 | 5.22K 7.14K | Capitalization | 563K 770K |
---|---|---|---|---|---|
Net income 2008 | - 0 | Net income 2009 | - 0 | EV / Sales 2008 | 33.3 x |
Net Debt 2008 | 399K 546K | Net Debt 2009 | 673K 920K | EV / Sales 2009 | 237 x |
P/E ratio 2008 |
-0.98
x | P/E ratio 2009 |
-1.34
x | Employees | 2 |
Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald S. Tucker
CEO | Chief Executive Officer | 84 | 97-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald S. Tucker
CEO | Chief Executive Officer | 84 | 97-09-30 |
1st Jan change | Capi. | |
---|---|---|
0.00% | 20 | |
+35.88% | 58B | |
+15.59% | 6.97B | |
-11.18% | 864M | |
-28.95% | 717M | |
+126.67% | 614M | |
+229.89% | 484M | |
-52.94% | 328M | |
-6.78% | 131M | |
-.--% | 118M |
- Stock Market
- Equities
- EPOR Stock